Dasatinib-induced Seborrheic Dermatitis-like Eruption

Ryan R Riahi1, Philip R Cohen1

  • 1Dr. Riahi is with DermSurgery Associates, Houston, Texas.

Insights

Dasatinib, used for chronic myelogenous leukemia, can cause seborrheic dermatitis-like skin issues. This case highlights a patient with melanoma experiencing this side effect during dasatinib treatment.

Area of Science:

  • Oncology
  • Dermatology

Background:

  • Dasatinib is a tyrosine kinase inhibitor approved for imatinib-resistant chronic myelogenous leukemia.
  • It is also explored for treating other cancers like non-small-cell lung cancer and melanoma.
  • Mucocutaneous side effects, such as seborrheic dermatitis, are common with antitumor agents.

Observation:

  • A 79-year-old woman with a history of sinonasal melanoma developed a seborrheic dermatitis-like eruption.
  • The patient was undergoing treatment with dasatinib.

Findings:

  • The case report details a patient experiencing a seborrheic dermatitis-like eruption while on dasatinib therapy.
  • The study reviews molecular abnormalities in melanoma and the mucocutaneous side effects of dasatinib.
  • Other antineoplastic agents linked to seborrheic dermatitis-like eruptions are also identified.

Implications:

  • This case underscores the potential for dasatinib to induce seborrheic dermatitis-like reactions.
  • Understanding these side effects is crucial for managing patients undergoing tyrosine kinase inhibitor therapy.
  • Further research may elucidate the mechanisms behind these drug-induced dermatologic conditions.

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.2K
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
32
Accessory Structures of the Skin: Sebaceous Glands01:21

Accessory Structures of the Skin: Sebaceous Glands

A sebaceous gland is a type of oil gland found almost all over the skin ( except palms and soles) and helps lubricate and waterproof the skin and hair. Most sebaceous glands are associated with hair follicles. They generate and excrete sebum, a mixture of lipids, onto the skin surface, thereby naturally lubricating the dry and dead layer of keratinized cells of the stratum corneum, keeping it pliable.
These glands that produce the oils on the skin and hair are holocrine glands. The mature...
4.7K
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.8K
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
43
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
719